Raymond James & Associates Invests $827,000 in Aspen Aerogels, Inc. (NYSE:ASPN)

Raymond James & Associates bought a new stake in Aspen Aerogels, Inc. (NYSE:ASPN) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 52,399 shares of the construction company’s stock, valued at approximately $827,000.

Several other large investors also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in Aspen Aerogels by 71.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,052 shares of the construction company’s stock valued at $198,000 after buying an additional 9,601 shares during the last quarter. Mesirow Financial Investment Management Inc. acquired a new stake in Aspen Aerogels during the third quarter valued at approximately $334,000. Principal Financial Group Inc. acquired a new stake in Aspen Aerogels during the third quarter valued at approximately $449,000. Levin Capital Strategies L.P. grew its stake in shares of Aspen Aerogels by 48.3% in the 3rd quarter. Levin Capital Strategies L.P. now owns 70,613 shares of the construction company’s stock valued at $607,000 after purchasing an additional 23,000 shares during the period. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in shares of Aspen Aerogels in the 3rd quarter worth approximately $659,000. Institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Canaccord Genuity Group boosted their price target on Aspen Aerogels from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, December 27th. Canaccord Genuity Group lifted their target price on shares of Aspen Aerogels from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday, December 27th. Roth Mkm started coverage on Aspen Aerogels in a report on Wednesday, March 6th. They set a “buy” rating and a $22.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aspen Aerogels in a research note on Wednesday, February 14th. Finally, TheStreet upgraded shares of Aspen Aerogels from a “d+” rating to a “c-” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Aspen Aerogels presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Aspen Aerogels Price Performance

Shares of ASPN opened at $15.17 on Tuesday. The stock’s 50-day moving average price is $16.52 and its two-hundred day moving average price is $13.15. Aspen Aerogels, Inc. has a 1 year low of $5.32 and a 1 year high of $19.10. The stock has a market cap of $1.16 billion, a P/E ratio of -22.98 and a beta of 2.04. The company has a current ratio of 3.41, a quick ratio of 2.91 and a debt-to-equity ratio of 0.24.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings results on Tuesday, February 13th. The construction company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.11. Aspen Aerogels had a negative net margin of 19.19% and a negative return on equity of 10.47%. The company had revenue of $84.22 million for the quarter, compared to analysts’ expectations of $83.82 million. During the same period last year, the firm posted ($0.20) earnings per share. On average, equities analysts predict that Aspen Aerogels, Inc. will post -0.24 earnings per share for the current year.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.